Exagen (XGN) Stock Statistics & Valuation Metrics

Exagen has a market cap or net worth of $153.02M. The enterprise value is $142.05M.

Exagen has 21,860,617 shares outstanding. The number of shares has decreased by -2.65% in one year.

Exagen’s return on equity (ROE) is -1.58 and return on invested capital (ROIC) is -43.18%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Exagen had revenue of 55.64M and earned -15.12M in profits. Earnings per share was -0.83.

In the last 12 months, operating cash flow was -14.91M and capital expenditures -542.00K, giving a free cash flow of -15.45M billion.

Exagen pays an annual dividend of ―, resulting in a dividend yield of ―

Exagen upcoming earnings date is Jul 29, 2025, After Close (Confirmed).

Exagen as a current ratio of 2.70, with Debt / Equity ratio of 78.57%

In the past 12 months, Exagen has paid 12.00K in taxes.

Exagen EV to EBITDA ratio is -6.78, with an EV/FCF ratio of -5.48.

Exagen has $11.19M in cash and marketable securities with $5.03M in debt, giving a net cash position of -$6.16M billion.

Gross margin is 59.30%, with operating margin of -24.51%, and net profit margin of -27.17%.

The average price target for Exagen is $8.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy